Nihon Shokuhin Kako Co.

Fuji, Japan

Nihon Shokuhin Kako Co.

Fuji, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Nihon Shokuhin Kako Co. and Morinaga Milk Industry Co. | Date: 2017-08-02

An object of the present invention is to provide a carbohydrate-derived energy supplying agent having slow digestibility and sustained digestibility functions. According to the present invention, there is provided a slowly digestible, sustained-type energy supplying agent comprising a saccharide composition which satisfies the following (A), (B), (C), and (D): (A) a percentage of -1,6 bonds relative to all glycosidic bonds is 60% or more; (B) a content of saccharides having a degree of polymerization of 1 and 2 relative to all saccharides is 9 mass% or less; (C) a content of saccharides having a degree of polymerization within a range of 3 to 30 relative to all saccharides is 41 mass% or more; and (D) a content of saccharides having a degree of polymerization of 31 or more relative to all saccharides is 50 mass% or less.


Patent
Kumamoto University and Nihon Shokuhin Kako Co. | Date: 2014-12-03

Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method for screening for said pharmaceutical compositions that uses iPS cell strains that phenocopy phentotypes of these disorders. Provided is a pharmaceutical composition for the treatment and/or prevention of lysosomal storage disease, characterized by containing hydroxypropyl--cyclodextrin as an active ingredient. Also provided are an iPS cell strain derived from patients suffering from intractable disorders and prepared using a new temperature-sensitive Sendai virus vector, and a screening method for pharmaceuticals using said iPS cell strain.


Hirotsu T.,Kumamoto University | Higashi T.,Kumamoto University | Hashim I.I.A.,Kumamoto University | Hashim I.I.A.,Mansoura University | And 4 more authors.
Molecular Pharmaceutics | Year: 2017

Polyethylene glycol (PEG) modification (PEGylation) is one of the best approaches to improve the stabilities and blood half-lives of protein drugs; however, PEGylation dramatically reduces the bioactivities of protein drugs. Here, we present "self-assembly PEGylation retaining activity" (SPRA) technology via a host-guest interaction between PEGylated β-cyclodextrin (PEG-β-CyD) and adamantane-appended (Ad) proteins. PEG-β-CyD formed stable complexes with Ad-insulin and Ad-lysozyme to yield SPRAinsulin and SPRA-lysozyme, respectively. Both SPRA-proteins showed high stability against heat and trypsin digest, comparable with that of covalently PEGylated protein equivalents. Importantly, the SPRA-lysozyme possessed ca. 100% lytic activity, whereas the activity of the covalently PEGylated lysozyme was ca. 23%. Additionally, SPRA-insulin provided a prolonged and peakless blood glucose profile when compared with insulin glargine. It also showed no loss of activity. In contrast, the covalently PEGylated insulin showed a negligible hypoglycemic effect. These findings indicate that SPRA technology has potential as a generic method, surpassing conventional PEGylation methods for proteins. © 2017 American Chemical Society.


Bito H.,Nihon Shokuhin Kako Co. | Hamaguchi N.,Nihon Shokuhin Kako Co. | Hirai H.,Nihon Shokuhin Kako Co. | Ogawa K.,Nihon Shokuhin Kako Co.
Journal of Toxicological Sciences | Year: 2016

Resistant glucan mixture (RGM), a water-soluble dietary fiber produced by the random polymerization of glucose with activated carbon as a catalyst at a high temperature, has been recently developed by our group. There has been little physiological and safety research into RGM and therefore we now present our research into its safety. A reverse mutation assay indicated that RGM is not mutagenic either with or without metabolic activation. We conducted a 90-day subchronic oral toxicity study in rats. Male and female rats fed either a 3% or 5% w/w RGM diet had no muddy or watery stools, and there was no RGM-related death in any group. Although some parameters in the 3% and 5% w/w groups were significantly different from those in the control group, these changes were not due to any toxicity from RGM. The results indicated that the No Observed Adverse Effect Level (NOAEL) of RGM was 3.3 and 3.9 g/kg body weight (BW) per day in male and female rats, respectively. We then studied the gastrointestinal effects of RGM in healthy adult humans. Gastrointestinal symptoms, such as gurgling sounds, flatus and tenesmus, were mild and transient. In men and women, the maximum no-effect dose for diarrhea was more than 0.9 g RGM /kg BW. The results of our current safety assessment studies suggest that RGM is safe for human consumption. © 2016, The Japanese Society of Toxicology. All rights reserved.


Ojima T.,Nihon Shokuhin Kako Co. | Saburi W.,Nihon Shokuhin Kako Co. | Saburi W.,Hokkaido University | Yamamoto T.,Nihon Shokuhin Kako Co. | Kudo T.,Nagasaki University
Applied and Environmental Microbiology | Year: 2012

An α-glucosidase (HaG) with the following unique properties was isolated from Halomonas sp. strain H11: (i) high transglucosylation activity, (ii) activation by monovalent cations, and (iii) very narrow substrate specificity. The molecular mass of the purified HaG was estimated to be 58 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). HaG showed high hydrolytic activities toward maltose, sucrose, and p-nitrophenyl α-D-glucoside (pNPG) but to almost no other disaccharides or malto-oligosaccharides higher than trisaccharides. HaG showed optimum activity to maltose at 30°C and pH 6.5. Monovalent cations such as K +, Rb +, Cs +, and NH 4 + increased the enzymatic activity to 2- to 9-fold of the original activity. These ions shifted the activity-pH profile to the alkaline side. The optimum temperature rose to 40°C in the presence of 10 mM NH 4 +, although temperature stability was not affected. The apparent K m and k cat values for maltose and pNPG were significantly improved by monovalent cations. Surprisingly, k cat/K m for pNPG increased 372- to 969-fold in their presence. HaG used some alcohols as acceptor substrates in transglucosylation and was useful for efficient synthesis of α-D-glucosylglycerol. The efficiency of the production level was superior to that of the previously reported enzyme Aspergillus niger α-glucosidase in terms of small amounts of by-products. Sequence analysis of HaG revealed that it was classified in glycoside hydrolase family 13. Its amino acid sequence showed high identities, 60%, 58%, 57%, and 56%, to Xanthomonas campestris WU-9701 α-glucosidase, Xanthomonas campestris pv. raphani 756C oligo-1,6-glucosidase, Pseudomonas stutzeri DSM 4166 oligo-1,6-glucosidase, and Agrobacterium tumefaciens F2 α-glucosidase, respectively. © 2012, American Society for Microbiology.


Ojima T.,Nihon Shokuhin Kako Co. | Aizawa K.,Nihon Shokuhin Kako Co. | Saburi W.,Hokkaido University | Yamamoto T.,Nihon Shokuhin Kako Co.
Carbohydrate Research | Year: 2012

6-Gingerol [(S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)decan-3-one] is a biologically active compound and is abundant in the rhizomes of ginger (Zingiber officinale). It has some beneficial functions in healthcare, but its use is limited because of its insolubility in water and its heat-instability. To improve these physical properties, the glucosylation of 6-gingerol was investigated using α-glucosidases (EC. 3.2.1.20) from Aspergillus niger, Aspergillus nidulans ABPU1, Acremonium strictum, Halomonas sp. H11, and Saccharomyces cerevisiae, and cyclodextrin glucanotransferases (CGTase, EC. 2.4.1.19) from Bacillus coagulans, Bacillus sp. No. 38-2, Bacillus clarkii 7364, and Geobacillus stearothermophilus. Among these, only α-glucosidase from Halomonas sp. H11 (HaG) transferred a glucosyl moiety to 6-gingerol, and produced glucosylated compounds. The chemical structure of the reaction product, determined by nuclear magnetic resonance spectroscopy and mass spectrometry, was (S)-5-(O-α-d-glucopyranosyl)-1-(4-hydroxy-3-methoxyphenyl)decan-3-one (5-α-Glc-gingerol). Notably, the regioisomer formed by glucosylation of the phenolic OH was not observed at all, indicating that HaG specifically transferred the glucose moiety to the 5-OH of the β-hydroxy keto group in 6-gingerol. Almost 60% of the original 6-gingerol was converted into 5-α-Glc-gingerol by the reaction. In contrast to 6-gingerol, 5-α-Glc-gingerol, in the form of an orange powder prepared by freeze-drying, was water-soluble and stable at room temperature. It was also more stable than 6-gingerol under acidic conditions and to heat. © 2012 Elsevier Ltd. All rights reserved.


Patent
Kumamoto University and Nihon Shokuhin Kako Co. | Date: 2016-10-12

Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method for screening for said pharmaceutical compositions that uses iPS cell strains that phenocopy phentotypes of these disorders. Provided is a pharmaceutical composition for the treatment and/or prevention of lysosomal storage disease, characterized by containing hydroxypropyl--cyclodextrin as an active ingredient. Also provided are an iPS cell strain derived from patients suffering from intractable disorders and prepared using a new temperature-sensitive Sendai virus vector, and a screening method for pharmaceuticals using said iPS cell strain.


Patent
Nihon Shokuhin Kako Co. | Date: 2015-12-02

The present invention addresses the problem of developing a fat-processed starch which is excellent in terms of all of three properties, i.e., workability during the preparation of a coating material for fries, function required of coating materials for fries (adhesion to ingredients) and moderate slurry viscosity. The fat-processed starch of the present invention is produced by a process comprising the steps: adding a fat with which an emulsifying agent has been mixed to a starch having a water content adjusted to 25 to 45 mass%, in an amount of 0.02 to 0.4 mass% in terms of the weight of the fat excluding the emulsifying agent relative to the weight of dry matter of the starch, and mixing the fat and the starch; adjusting the water content of the mixture is 0.2 to 0.5 time that of the starch before the addition of the fat; and aging the starch having the adjusted water content.


Patent
Nihon Shokuhin Kako Co. | Date: 2013-04-23

The present invention addresses the problem of developing a fat-processed starch which is excellent in terms of all of three properties, i.e., workability during the preparation of a coating material for fries, function required of coating materials for fries (adhesion to ingredients) and moderate slurry viscosity. The fat-processed starch of the present invention is produced by a process comprising the steps: adding a fat with which an emulsifying agent has been mixed to a starch having a water content adjusted to 25 to 45 mass %, in an amount of 0.02 to 0.4 mass % in terms of the weight of the fat excluding the emulsifying agent relative to the weight of dry matter of the starch, and mixing the fat and the starch; adjusting the water content of the mixture is 0.2 to 0.5 time that of the starch before the addition of the fat; and aging the starch having the adjusted water content.


Patent
Nihon Shokuhin Kako Co. | Date: 2013-11-13

An object of the present invention is to provide a method for producing a saccharide polycondensate which is inexpensive and is applicable to a food or beverage product. Disclosed is a method for producing a saccharide polycondensate, which comprises carrying out a saccharide polycondensation reaction in the presence of activated carbon.

Loading Nihon Shokuhin Kako Co. collaborators
Loading Nihon Shokuhin Kako Co. collaborators